20 January 2016
Catapult Ventures appoints Dr Gareth King as Investment Manager
Catapult Ventures has announced the appointment of Dr Gareth King to its new GM&C Life Sciences Fund where he will be Investment Manager. Dr King joins Catapult from Critical Pharmaceuticals, a Catapult life sciences portfolio company, where he has been CEO for the last four years.
Speaking on the new appointment, Catapult CEO Nick Wright said: “I am delighted to welcome Gareth to Catapult as the first Investment Manager of our new GM&C Life Sciences Fund. Catapult has known Gareth for many years and we have always been impressed with his deal making ability and leadership qualities. He has an excellent track record of working in the biotech and pharma industries for UK and international companies at a senior level. Gareth has lived in Wilmslow for many years and he previously spent several years with Astra Zeneca at Alderley Park, where our new fund is based, so we also benefit from his local knowledge and contacts.”
Commenting on his new appointment, Dr King said: “I am delighted to be joining Catapult at this very exciting time, helping to launch the new life science fund for the Greater Manchester and Cheshire region. I’ve already met a wide range of exciting start-up and early-stage companies and look forward to building several world-leading life science companies in the region.”
The GM&C Life Sciences Fund is a specialist seed and early stage venture capital fund targeting life sciences businesses with a presence in the Greater Manchester and Cheshire & Warrington region. With a first close of around £31m, the fund is actively seeking to invest in high-potential innovative companies.
Catapult also announced the appointment of Sam Bailey as Office Manager for the GM&C Life Science Fund. Sam has worked at ICI, Zeneca and AstraZeneca for 23 years in various departments across Alderley Park and Macclesfield and was most recently an administrator for BioHub in Alderley Park.